secwatch.observer — SEC 8-K summary
======================================

Issuer:     Stoke Therapeutics, Inc. (STOK)
CIK:        0001623526
Form:       8-K
Filed at:   2026-03-03T23:59:59+00:00
Accession:  0001193125-26-088205
Event type: other_material
Sentiment:  positive
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Stoke Therapeutics awards CEO Ian F. Smith $697K discretionary bonus for 2025
-----------------------------------------------------------------------------

- Discretionary bonus of $697,125 for CEO Ian F. Smith, equal to full target bonus for 2025.
- Smith did not participate in 2025 annual bonus program; Board determined corporate goal achievement at 150% of target.
- Bonus based on clinical and financial performance since Smith's appointment as interim CEO in March 2025 and permanent CEO in Oct 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1623526/000119312526088205/0001193125-26-088205-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1623526/000119312526088205/d57138d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-088205

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer